Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study

Dupilumab was found to be associated with significant improvement in CC in 50% (<i>n</i>=10) of patients with SEA, in 73% (<i>n</i>=19) of patients with CRSwNP, and in 62% (<i>n</i>=13) of patients with SEA plus CRSwNP, respectively. In this real-life study, dupilumab significantly reduced CC whilst improving quality of life in patients with SEA with or without CRSwNP. These results support the potential role of dupilumab in the treatment of cough as a treatable trait.